Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

March 26, 2015 4:10 PM ET

Company Overview of University of Geneva

Company Overview

University of Geneva is an educational institution.

24, rue du Général-Dufour

Geneva,  1211


Founded in 2004


41 22 379 71 11


41 22 379 11 34

Key Executives for University of Geneva

University of Geneva does not have any Key Executives recorded.

University of Geneva Key Developments

DBV Technologies Enters into Collaboration Agreement with BioNet-Asia and University of Geneva on Whooping Cough Booster Vaccine

DBV Technologies announced that it has entered into a collaboration agreement with BioNet-Asia Co. Ltd. and the University of Geneva (UNIGE) to work on a whooping cough (pertussis) booster vaccine. The clinical proof of concept product candidate will combine BioNet's unique recombinant non-toxic Pertussis Toxin (rPT) with DBV's Viaskin(R) technology, which allows for the epicutaneous delivery of the antigen without any adjuvant. The DBV-BioNet-UNIGE research and development collaboration will consist of a non-clinical component and a clinical development program. The Non-Clinical Study Program will measure the specific immunity and protective responses elicited by a Viaskin pertussis antigens boost in a Bordetella pertussis respiratory murine model. The Clinical Study Program will be initiated in the second half of 2014 to evaluate the boosting influence of recombinant non-toxic pertussis toxin delivered by Viaskin in a Phase I, proof-of-concept, study performed under the responsibility of Pr. Siegrist from the University of Geneva, Switzerland. This Phase I clinical trial will assess the safety and immunogenicity of Viaskin-PT and evaluate the humoral and cellular responses in healthy adults.

University of Geneva Presents at Wells Fargo Securities Inaugural E-Cig Forum, Nov-21-2013 09:55 AM

University of Geneva Presents at Wells Fargo Securities Inaugural E-Cig Forum, Nov-21-2013 09:55 AM. Venue: The New York Palace Hotel, New York, New York, United States. Speakers: Jean-Francois Etter, PhD, Associate Professor, Faculty of Medicine.

Similar Private Companies By Industry

Company Name Region
Karl Bleuler AG Europe
Cardinal Health Switzerland 413 AG Europe
Via Handels AG Europe
SI Prelude Europe
Bolzern Kommunikation AG Europe

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
NYC2012, Inc. United States
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact University of Geneva, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at